MAPT and early-onset autosomal dominant Alzheimer disease: Preclinical Evidence characterizes compounds demonstrating therapeutic effects in validated Alzheimer’s disease animal models (APP/PS1, 3xTg-AD, 5xFAD transgenic mice, rat models) or human-derived cellular systems (iPSC-derived neurons, brain organoids, primary neuronal cultures) with documented effects on AD-relevant pathologies including amyloid-β aggregation, tau phosphorylation, synaptic loss, neuroinflammation, or cognitive deficits.